Within this review, an overview of the structural changes influencing the functionality of cells is given, followed by NPM1-mutated AML risk stratification, monitoring of NPM1 mutants by MRD, and finally targeting NPM1-mutations for treatment of AML patients. The gene discussed is NPM1; the disease is acute myeloid leukemia.